Lazar Mandinov
Corporate Officer/Principal presso The European Society of Cardiology
Profilo
Lazar Mandinov is a member of The European Society of Cardiology.
He previously worked as a Medical Director at Boston Scientific Corp., Chief Medical Officer at Mitralign, Inc., and Principal at Maine Medical Center Research.
Dr. Mandinov holds a doctorate degree from Medical University Sofia.
Posizioni attive di Lazar Mandinov
| Società | Posizione | Inizio |
|---|---|---|
| The European Society of Cardiology | Corporate Officer/Principal | - |
Precedenti posizioni note di Lazar Mandinov
| Società | Posizione | Fine |
|---|---|---|
| BOSTON SCIENTIFIC CORPORATION | Direttore Tecnico/Scientifico/R&S | - |
| Maine Medical Center Research | Corporate Officer/Principal | - |
Mitralign, Inc.
 Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Lazar Mandinov
| Medical University Sofia | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| BOSTON SCIENTIFIC CORPORATION | Health Technology |
| Aziende private | 3 |
|---|---|
Mitralign, Inc.
Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | Health Technology |
| The European Society of Cardiology | |
| Maine Medical Center Research |
- Borsa valori
- Insiders
- Lazar Mandinov
